In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer.
about
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic AdenovirusEnhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator.Oncolytic virotherapy for urological cancers.Oncolytic viruses: the power of directed evolution.Human telomerase reverse-transcriptase promoter-controlled and herpes simplex virus thymidine kinase-armed adenoviruses for renal cell carcinoma treatment.Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
P2860
In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
In vitro analysis of cidofovir ...... Ad1-based treatment of cancer.
@en
In vitro analysis of cidofovir ...... Ad1-based treatment of cancer.
@nl
type
label
In vitro analysis of cidofovir ...... Ad1-based treatment of cancer.
@en
In vitro analysis of cidofovir ...... Ad1-based treatment of cancer.
@nl
prefLabel
In vitro analysis of cidofovir ...... Ad1-based treatment of cancer.
@en
In vitro analysis of cidofovir ...... Ad1-based treatment of cancer.
@nl
P2093
P2860
P356
P1433
P1476
In vitro analysis of cidofovir ...... Ad1-based treatment of cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2009.69
P577
2009-05-21T00:00:00Z
P5875
P6179
1041005550